These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Immune monitoring of cancer patients undergoing experimental immunotherapy. Shankar G; Salgaller ML Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653 [TBL] [Abstract][Full Text] [Related]
24. Cell based cancer vaccines: regulatory and commercial development. Copier J; Ward S; Dalgleish A Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462 [TBL] [Abstract][Full Text] [Related]
25. The relevance of cytokines for development of protective immunity and rational design of vaccines. Chabalgoity JA; Baz A; Rial A; Grille S Cytokine Growth Factor Rev; 2007; 18(1-2):195-207. PubMed ID: 17347024 [TBL] [Abstract][Full Text] [Related]
26. New frontiers in cell-based immunotherapy of cancer. D'Elios MM; Del Prete G; Amedei A Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938 [TBL] [Abstract][Full Text] [Related]
28. Gene transfer approaches in cancer immunotherapy. Larin SS; Georgiev GP; Kiselev SL Gene Ther; 2004 Oct; 11 Suppl 1():S18-25. PubMed ID: 15454953 [TBL] [Abstract][Full Text] [Related]
29. Reversal of tumor-mediated immunosuppression. Vieweg J; Su Z; Dahm P; Kusmartsev S Clin Cancer Res; 2007 Jan; 13(2 Pt 2):727s-732s. PubMed ID: 17255301 [TBL] [Abstract][Full Text] [Related]
30. Dendritic cells and their role in cancer immunotherapy. Jalili A Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012 [TBL] [Abstract][Full Text] [Related]
31. Targeted therapies to improve tumor immunotherapy. Begley J; Ribas A Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452 [TBL] [Abstract][Full Text] [Related]
32. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
33. Immunotherapeutic strategies employing RNA interference technology for the control of cancers. Mao CP; Hung CF; Wu TC J Biomed Sci; 2007 Jan; 14(1):15-29. PubMed ID: 17103251 [TBL] [Abstract][Full Text] [Related]
34. From cancer immunosurveillance to cancer immunotherapy. Stagg J; Johnstone RW; Smyth MJ Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841 [TBL] [Abstract][Full Text] [Related]
35. How immunotherapy can enhance the response to other modalities and improve outcome and quality of life. Liu WM; Meyer B; Dalgleish AG J BUON; 2009 Sep; 14 Suppl 1():S103-9. PubMed ID: 19785052 [TBL] [Abstract][Full Text] [Related]
36. Tumor-host immune interactions and dendritic cell dysfunction. Yang L; Carbone DP Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555 [TBL] [Abstract][Full Text] [Related]